These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 27177330)

  • 1. mTOR: An attractive therapeutic target for osteosarcoma?
    Ding L; Congwei L; Bei Q; Tao Y; Ruiguo W; Heze Y; Bo D; Zhihong L
    Oncotarget; 2016 Aug; 7(31):50805-50813. PubMed ID: 27177330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review).
    Hu K; Dai HB; Qiu ZL
    Oncol Rep; 2016 Sep; 36(3):1219-25. PubMed ID: 27430283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
    Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L
    IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway.
    Liu B; Xu L; Dai EN; Tian JX; Li JM
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30442873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Norcantharidin inhibits proliferation and promotes apoptosis via c-Met/Akt/mTOR pathway in human osteosarcoma cells.
    Mei L; Sang W; Cui K; Zhang Y; Chen F; Li X
    Cancer Sci; 2019 Feb; 110(2):582-595. PubMed ID: 30520540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LHX2 promotes malignancy and inhibits autophagy via mTOR in osteosarcoma and is negatively regulated by miR-129-5p.
    Song H; Liu J; Wu X; Zhou Y; Chen X; Chen J; Deng K; Mao C; Huang S; Liu Z
    Aging (Albany NY); 2019 Nov; 11(21):9794-9810. PubMed ID: 31724536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
    Fleuren ED; Versleijen-Jonkers YM; Roeffen MH; Franssen GM; Flucke UE; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
    Int J Cancer; 2014 Dec; 135(12):2770-82. PubMed ID: 24771207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition.
    Liao YX; Lv JY; Zhou ZF; Xu TY; Yang D; Gao QM; Fan L; Li GD; Yu HY; Liu KY
    Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34080667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway.
    Zhang Y; Zhang T; Chen L; Guo Z; Jiang X
    Aging (Albany NY); 2024 Jun; 16(14):11208-11223. PubMed ID: 39024509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor β induces autophagy of osteosarcoma through the mTOR signaling pathway.
    Yang Z; Yu W; Liu B; Yang M; Tao H
    J Orthop Surg Res; 2020 Feb; 15(1):50. PubMed ID: 32054506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells.
    Zhou R; Zhang Z; Zhao L; Jia C; Xu S; Mai Q; Lu M; Huang M; Wang L; Wang X; Jin D; Bai X
    J Orthop Res; 2011 Jun; 29(6):846-52. PubMed ID: 21246613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physakengose G induces apoptosis via EGFR/mTOR signaling and inhibits autophagic flux in human osteosarcoma cells.
    Lin H; Zhang C; Zhang H; Xia YZ; Zhang CY; Luo J; Yang L; Kong LY
    Phytomedicine; 2018 Mar; 42():190-198. PubMed ID: 29655686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma.
    Yang J; Cheng D; Zhou S; Zhu B; Hu T; Yang Q
    Int J Mol Sci; 2015 Dec; 16(12):28635-46. PubMed ID: 26633383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inhibitory effect and significance of rapamycin on the mammalian target of rapamycin signaling pathway in osteosarcoma stem cells and osteosarcoma cells].
    Liu PY; Zhang WB; Wang J; Shen YH; Wei YY
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):175-80. PubMed ID: 23879996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma.
    Jiang H; Zeng Z
    Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):255-61. PubMed ID: 26514724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models.
    Zhu YR; Zhou XZ; Zhu LQ; Yao C; Fang JF; Zhou F; Deng XW; Zhang YQ
    Oncotarget; 2016 Aug; 7(31):49527-49538. PubMed ID: 27385099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CLG promotes mTOR/ULK1 pathway-mediated autophagy to inhibit OS development by inhibiting TRAF6-mediated FLT3 ubiquitination.
    Huang X; Huang Y; Peng B; Wang J; Tang H; Chen Y
    Cancer Sci; 2024 Oct; 115(10):3466-3480. PubMed ID: 39118482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chitooligosaccharides inhibit tumor progression and induce autophagy through the activation of the p53/mTOR pathway in osteosarcoma.
    Pan Z; Cheng DD; Wei XJ; Li SJ; Guo H; Yang QC
    Carbohydr Polym; 2021 Apr; 258():117596. PubMed ID: 33593530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529.
    Hu X; Wang Z; Chen M; Chen X; Liang W
    Biochem Biophys Res Commun; 2018 Mar; 497(2):499-505. PubMed ID: 29432734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.